Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2018

View Archived Issues

Eli Lilly initiates phase I study of LY-3316531

Researchers discover new class of calcium-dependent antibiotics

FDA approves phase I/II study of ABTL-0812 in patients with advanced metastatic pancreatic cancer

BirchBioMed's topical kynurenic acid formulation is safe in healthy volunteers

FUJIFILM RI Pharma begins phase II studies of F-1641 for refractory pheochromocytoma in Japan

Jiangsu Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery patent PTGDR2 antagonists

Roche discovers novel mGlu4 receptor positive allosteric modulators

ISA Pharmaceuticals, Scancell enter collaboration agreement to develop Modi-1

TP Therapeutics describes novel BTK/JAK2/NTRK1 inhibitors

Ki-67 and AZGP1 shown as predictors of prostate cancer metastasis and death

FDA grants orphan drug designation to siplizumab to prevent solid organ transplant rejection

Gene therapy for limb girdle muscular dystrophy type 2E granted FDA orphan title

Biomarker panel tied to mucosal healing in adalimumab-treated ulcerative colitis patients

Erdafitinib active in phase II study in urothelial carcinoma with FGFR alterations

Rabies vaccine YS-ON-001 named an FDA orphan drug for pancreatic cancer

Zealand Pharma and UniQuest begin venom-based collaboration for gastrointestinal diseases

Tessa Therapeutics patents GPC3-targeting CARs

Phase II development of LY-3337641 for rheumatoid arthritis ended

Researchers in Korea patent LRG1-containing fusion proteins

Disease control seen with pexastimogene devacirepvec in metastatic, refractory renal cell carcinoma

Veritas Pharma plans to take over remaining 20% of Cannevert

Kancera considers development of KAND-567 in cancer and cardiovascular disease

AbbVie and Voyager collaborate to develop vectorized antibodies against tau

PDL BioPharma will no longer pursue Neos Therapeutics

Minoryx spins off SEE-Tx platform into Gain Therapeutics

Tell us what you think about TRDN

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...